Nutritional supplement research concerning brain health and neurological disease is becoming an important focus. While nutritional supplements are very popular for general health and well being, the effectiveness of common supplements and their impact on general brain health and for the treatment or prevention of neurological disease is not clearly understood. This comprehensive introduction to bioactive nutraceuticals for brain and neurological provides a foundation review for research neuroscientists, clinical neurologists, pharmacology researchers and nutrition scientists on what we know now about these supplements and the brain and where focused research is still necessary.
- Foundational review content covering nutrition and brain and neurological health
- Reviews known nutritional supplements and impact on brain and neurological health
- Comprehensive coverage ideal for research scientists and clinical practitioners
Inhaltsverzeichnis
1;Front Cover;1 2;BIOACTIVE NUTRACEUTICALS AND DIETARY SUPPLEMENTS IN NEUROLOGICAL AND BRAIN DISEASE;4 3;Copyright;5 4;Contents;6 5;Preface;14 6;About the Editors;16 7;Contributors;18 8;Acknowledgments;22 9;SECTION I - THE ROLE OF COMPLEMENTARYAND ALTERNATIVE SUPPLEMENTS:;24 9.1;Chapter 1 - Anti-Inflammatory Properties of Botanical Extracts Contribute to Their Protective Effects in Brain Edema in Cerebral Ischemia;26 9.1.1;INTRODUCTION;26 9.1.2;ROLE OF PROINFLAMMATORY PROTEINS IN BRAIN EDEMA IN ISCHEMIC INJURY;27 9.1.3;THE ROLE OF BOTANICAL EXTRACTS IN ATTENUATING BRAIN EDEMA AND CELL SWELLING IN ISCHEMIA;28 9.1.4;THE ROLE OF BOTANICAL EXTRACTS IN REDUCING INFLAMMATION IN INJURY;30 9.1.5;CONCLUSION;30 9.1.6;CONFLICT OF INTEREST STATEMENT;30 9.1.7;Acknowledgments;34 9.1.8;References;34 9.2;Chapter 2 - Blueberry Polyphenols and Neuroprotection;40 9.2.1;INTRODUCTION;40 9.2.2;BLUEBERRY POLYPHENOLS;40 9.2.3;NEURODEGENERATION: MECHANISMS AND IMPLICATIONS FOR BRAIN PERFORMANCE;42 9.2.4;NEUROPROTECTIVE EFFECTS OF BLUEBERRY POLYPHENOLS;43 9.2.5;CONCLUSIONS;48 9.2.6;References;48 9.3;Chapter 3 - Neuropharmacology Effects of Saffron (Crocus sativus) and Its Active Constituents;52 9.3.1;INTRODUCTION;52 9.3.2;ANIMAL STUDIES;54 9.3.3;CLINICAL STUDIES;59 9.3.4;CONCLUSION;59 9.3.5;References;59 9.4;Chapter 4 - Lutein, Brain, and Neurological Functions;64 9.4.1;ADULTS AND COGNITIVE FUNCTION;65 9.4.2;EYEBRAIN CONNECTION;65 9.4.3;CAROTENOIDS IN EYE AND BRAIN;65 9.4.4;EARLY LIFE PERIOD;66 9.4.5;INFLUENCE OF CAROTENOIDS ON BRAIN FUNCTIONS;67 9.4.6;LUTEIN AND COGNITIVE FUNCTION;68 9.4.7;LUTEIN AND PARKINSONS DISEASE;68 9.4.8;LUTEIN AND HUNTINGTONS DISEASE;69 9.4.9;CONCLUSION;69 9.4.10;References;69 9.5;Chapter 5 - Bioactive Nutrients for Brain Health: An Overview;72 9.5.1;An Overview;72 9.5.2;DIET AND COGNITIVE FUNCTION;74 9.5.3;References;77 9.6;Chapter 6 - Using Paullinia cupana (Guarana) to Treat Fatigue and Other Symptoms of Cancer and Cancer Treatment;80 9.6.1;INTRODUCTION;80 9.6.2;
PAULLINIA CUPANA (GUARANA);80 9.6.3;CANCER-RELATED FATIGUE;81 9.6.4;THE USE OF GUARANA FOR CRF TREATMENT;82 9.6.5;MECHANISM OF ACTION OF GUARANA IN PATIENTS WITH CRF;83 9.6.6;PRELIMINARY DATA ON THE DRY GUARANA EXTRACT FOR TERMINAL CANCER PATIENTS WITH HISTORY OF WEIGHT LOSS (TUMOR CACHEXIA);83 9.6.7;PRELIMINARY DATA ON DRY GUARANA EXTRACT FOR TREATMENT OF HOT FLASHES IN BREAST CANCER SURVIVORS;85 9.6.8;References;86 9.7;Chapter 7 - Polyphenols, Nerve Growth Factor, Brain-Derived Neurotrophic Factor, and the Brain;88 9.7.1;THE BRAIN;88 9.7.2;NEUROTROPHINS;88 9.7.3;POLYPHENOLS;89 9.7.4;POLYPHENOLS AND THE BRAIN;90 9.7.5;POLYPHENOLS AND NEUROTROPHINS;91 9.7.6;CONCLUSIONS;92 9.7.7;DISCLOSURE;92 9.7.8;References;92 9.8;Chapter 8 - The Antiaggregative, Antiamyloid Properties of Bioactive Polyphenols in the Treatment of Alzheimers Disease;96 9.8.1;INTRODUCTION;96 9.8.2;(-) EPIGALLOCATECHIN-3-GALLATE;97 9.8.3;CURCUMIN;97 9.8.4;RESVERATROL;98 9.8.5;CONCLUSION;98 9.8.6;References;98 9.9;Chapter 9 - Rhinacanthus Nasutus Extract as a Neuroprotectant;100 9.9.1;RHINACANTHUS NASUTUS PROPERTIES AND USE IN TRADITIONAL MEDICINE;100 9.9.2;RHINACANTHUS NASUTUS AND ITS EMERGING POTENTIAL ROLE AS A NEUROPROTECTANT;103 9.9.3;RHINACANTHUS NASUTUS, IMMUNE RESPONSE, AND NEUROPROTECTION;104 9.9.4;References;106 10;SECTION II - ROLE OF DIETS, COMPLEMENTARY, AND ALTERNATIVE SUPPLEMENTS IN PREVENTION AND TREATMENT OF NEURODEGENERATIVE DISEASES;108 10.1;Chapter 10 - Nutraceuticals, Dietary Supplements, and Functional Foods as Alternatives for the Relief of Neuropathic Pain;110 10.1.1;NUTRACEUTICALS AND FOOD SUPPLEMENTS AND NEUROPATHIC PAIN TREATMENT;112 10.1.2;CONCLUSION;114 10.1.3;References;114 10.2;Chapter 11 - The Therapeutic Activities of Selected Scrophulariaceae and Buddlejaceae Species and Their Secondary Metabolites Against Neurodegenerative Diseases;118 10.2.1;INTRODUCTION;118 10.2.2;VERBASCUM SPECIES (MULLEIN) AND THEIR THERAPEUTIC ACTIVITIES AGAINST NEURODEGENERATIVE DISEASES;121 10.
2.3;SCROPHULARIA SPECIES (FIGWORT) AND THEIR THERAPEUTIC ACTIVITIES AGAINST NEURODEGENERATIVE DISEASES;123 10.2.4;BUDDLEJA SPECIES (BUTTERFLY BUSH) AND THEIR THERAPEUTIC ACTIVITIES AGAINST NEURODEGENERATIVE DISEASES;126 10.2.5;SECONDARY METABOLITES AND THEIR THERAPEUTIC ACTIVITIES AGAINST NEURODEGENERATIVE DISEASES;129 10.2.6;CONCLUSION;132 10.2.7;References;132 10.3;Chapter 12 - Ginkgo biloba Extracts in Neurological Disorders Therapy: Clinical Trials;136 10.3.1;Clinical Trials;136 10.3.2;INTRODUCTION;136 10.3.3;MEDICAL USES;137 10.3.4;DOSAGE AND DURATION;138 10.3.5;NORMAL COGNITIVE FUNCTIONING;138 10.3.6;AGE-RELATED COGNITIVE IMPAIRMENT;138 10.3.7;AGE-RELATED DEMENTIA AND ALZHEIMERS DISEASE;139 10.3.8;DEMENTIA AND ALZHEIMERS DISEASE;141 10.3.9;MULTIPLE SCLEROSIS;143 10.3.10;TARDIVE DYSKINESIA;143 10.3.11;META-ANALYSIS AND SYSTEMATIC REVIEWS OF GINKGO CLINICAL TRIALS;144 10.3.12;SIDE EFFECTS AND QUALITY ISSUES OF EGB 761;144 10.3.13;EXPOSURE TO GINKGO LEAF EXTRACTS IN CLINICAL STUDIES;145 10.3.14;CONCLUSION;145 10.3.15;References;146 10.4;Chapter 13 - The Ketogenic Diet for the Adjuvant Treatment of Malignant Brain Tumors;148 10.4.1;INTRODUCTION;148 10.4.2;TUMOR METABOLISM;148 10.4.3;THE KETOGENIC DIET;149 10.4.4;MECHANISMS OF ACTION;150 10.4.5;CASE STUDIES AND CLINICAL TRIALS;154 10.4.6;IMPLEMENTATION OF THE KD;154 10.4.7;CONCLUSIONS;155 10.4.8;References;156 10.5;Chapter 14 - Reduction is the New Youth: The Effect of Polyphenols on Brain Aging and Diseases;160 10.5.1;The Effect of Polyphenols on Brain Aging and Diseases;160 10.5.2;CONCLUSION;162 10.5.3;References;163 10.6;Chapter 15 - Natural Sleep Aids and Polyphenols as Treatments for Insomnia;164 10.6.1;INTRODUCTION;164 10.6.2;HERBAL SUPPLEMENTS FOR TREATING INSOMNIA;165 10.6.3;HYPNOTIC EFFECTS OF TERRESTRIAL PLANT POLYPHENOLS;166 10.6.4;HYPNOTIC EFFECTS OF MARINE PLANT POLYPHENOLS;170 10.6.5;CONCLUSION;172 10.6.6;References;172 10.7;Chapter 16 - The Effects of Trace Element Deficiencies on Neurological Diseas
e and Treatment with Trace Element Support;176 10.7.1;INTRODUCTION;176 10.7.2;ZINC DEFICIENCY, NEUROLOGICAL DISORDERS, AND ZINC SUPPLEMENT;177 10.7.3;NEUROLOGICAL DISEASES AND MG SUPPLEMENT;178 10.7.4;SELENIUM AND NEUROLOGICAL DISEASES;178 10.7.5;IRON DEFICIENCY AND BRAIN DISEASES;179 10.7.6;COPPER DEFICIENCY AND BRAIN DISEASES;180 10.7.7;IODINE DEFICIENCY AND IODINE SUPPLEMENTATION IN NEUROLOGICAL DISORDERS;180 10.7.8;CONCLUSION;180 10.7.9;References;181 10.8;Chapter 17 - Nutritional Supplementation in Ehlers-Danlos Syndrome;184 10.8.1;INTRODUCTION;184 10.8.2;IS EHLERS-DANLOS SYNDROME A NEUROLOGICAL DISORDER?;186 10.8.3;DIETARY FACTS IN EHLERS-DANLOS SYNDROME;187 10.8.4;NUTRITIONAL RESOURCES BY CLINICAL FEATURE;187 10.8.5;CONCLUSIONS;190 10.8.6;References;191 11;SECTION III - MOOD AND COGNITION BY NUTRACEUTICAL INTERVENTIONS;194 11.1;Chapter 18 - Ayurvedic Approach to Food and Dietary Supplements for the Brain and Neurologic Health;196 11.1.1;INTRODUCTION;196 11.1.2;THE THREE DOSHAS;196 11.1.3;IMPORTANCE OF DIET AND DIGESTION;197 11.1.4;SHADARASA (SIX TYPES OF TASTE);197 11.1.5;PSYCHOLOGICAL CONSTITUTION AND FOOD;197 11.1.6;AYURVEDIC CONCEPT OF VYADHI (DISEASE);197 11.1.7;VIRUDDHA AHARA (INCOMPATIBLE FOODS);198 11.1.8;FOODS THAT ARE BENEFICIAL FOR THE BRAIN AND NEUROLOGICAL HEALTH;198 11.1.9;HERBS AND HERBAL MIXTURES FOR THE BRAIN AND NEUROLOGICAL HEALTH;198 11.1.10;GHEE AS A THERAPEUTIC VEHICLE;199 11.1.11;CONCLUSION;200 11.1.12;Acknowledgments;200 11.1.13;References;200 11.2;Chapter 19 - The Effect of Acai (Euterpe spp.) Fruit Pulp on Brain Health and Performance;202 11.2.1;INTRODUCTION;202 11.2.2;ACAI FRUIT PULP;203 11.2.3;CONCLUSION;207 11.2.4;References;207 11.3;Chapter 20 - Chili Pepper Compounds in the Management of Neuropathic Pain;210 11.3.1;INTRODUCTION;210 11.3.2;CHILI PEPPER AND ITS COMPOUNDS;210 11.3.3;PHARMACOLOGICAL FEATURES OF CAPSAICIN;212 11.3.4;FORMULATIONS OF TOPICAL CAPSAICIN;214 11.3.5;CAPSAICIN FOR THE TREATMENT OF PERIPHERAL NEUROPATHIC PAIN
;214 11.3.6;CONCLUSIONS;215 11.3.7;References;216 11.4;Chapter 21 - Curcumin and Neurological/Brain Disorders;220 11.4.1;INTRODUCTION;220 11.4.2;HERBAL MEDICINES AND NERVOUS SYSTEM;221 11.4.3;CURCUMIN;222 11.4.4;A CURCUMIN SOURCE WITH ENHANCED BIOAVAILABILITY;223 11.4.5;CONCLUSION;224 11.4.6;References;224 12;SECTION IV - DRUGS AND FOODS AND NUTRACEUTICAL INTERACTIONS DURING TREATMENT OF NEURODEGENERATIVE DISEASES:TOXICITIES;228 12.1;Chapter 22 - The Effects of Taurine Exposure on the Brain and Neurological Disorders;230 12.1.1;INTRODUCTION;230 12.1.2;TAURINE DEVELOPMENTAL DISTRIBUTION IN THE BRAIN;230 12.1.3;TAURINE BIOSYNTHESIS IN THE BRAIN;231 12.1.4;BLOODBRAIN TAURINE TRANSPORT;232 12.1.5;ACTIONS OF TAURINE IN THE BRAIN;233 12.1.6;TAURINE IN LEARNING AND MEMORY;233 12.1.7;TAURINE IN NEURAL CONTROL OF ARTERIAL PRESSURE;234 12.1.8;References;235 12.2;Chapter 23 - Adverse Neurological Effects Caused by the Ingestion of Plants, Seeds, and Fruits;238 12.2.1;INTRODUCTION;238 12.2.2;CONSUMPTION OF TOXIC PLANTS IN THE DIET;238 12.2.3;HEALING PLANTS;239 12.2.4;ACUTE INTOXICATIONS DUE TO TOXIC PLANTS;239 12.2.5;HALLUCINOGENIC PLANTS AND CACTI;240 12.2.6;FUNGI AND MYCOTOXINS;241 12.2.7;CONCLUSION;242 12.2.8;References;242 12.3;Chapter 24 - Molecular Mechanisms of Geniposide and Genipin Against Alzheimers Disease;244 12.3.1;ANTI-A. TOXICITY;245 12.3.2;ANTI-OXIDATIVE STRESS;245 12.3.3;ANTIENDOPLASMIC RETICULUM STRESS;246 12.3.4;ANTI-INFLAMMATION;246 12.3.5;PROMOTING NEURITE OUTGROWTH;247 12.3.6;ACTIVATION OF GLUCAGON-LIKE PEPTIDE 1 RECEPTOR (GLP-1R);248 12.3.7;SUMMARY;248 12.3.8;Acknowledgments;248 12.3.9;References;249 12.4;Chapter 25 - Flavones and Flavonols in Brain and Disease: Facts and Pitfalls;252 12.4.1;Facts and Pitfalls;252 12.4.2;BRAIN PATHOLOGY: OXIDATIVE STRESS AND INFLAMMATION;252 12.4.3;FLAVONES AND FLAVONOLS: CHEMICAL AND STRUCTURAL FEATURES;253 12.4.4;BRAIN EFFECTS OF FLAVONES AND FLAVONOLS: IN VIVO EVIDENCE;253 12.4.5;WORKING MECHANISMS UNDERLYING THE BRAIN
EFFECTS OF FLAVONES AND FLAVONOLS: IN VITRO EVIDENCE;255 12.4.6;CONCLUSION;258 12.4.7;References;258 12.5;Chapter 26 - Mercury and Neurodegeneration;260 12.5.1;SOURCES OF MERCURY EXPOSURE;260 12.5.2;HG METABOLISM;261 12.5.3;INTERACTIONS WITH OTHER DIETARY FACTORS;262 12.5.4;ROLE OF HG IN NEUROLOGICAL PATHOLOGY;262 12.5.5;TREATMENT;264 12.5.6;References;265 12.6;Chapter 27 - Ameliorative Effects of Nutraceuticals in Neurological Disorders;268 12.6.1;INTRODUCTION;268 12.6.2;GARLIC (ALLIUM SATIVUM);270 12.6.3;CURCUMIN (CURCUMA LONGA L);271 12.6.4;ASHWAGANDHA (WITHANIA SOMNIFERA);271 12.6.5;BRAHMI (BACOPA MONNIERI);272 12.6.6;BERRIES;274 12.6.7;ALMONDS (PRUNUS DULCIS/AMYGDALUS L.) AND WALNUTS (JUGLANS REGIA L.);275 12.6.8;MECHANISMS OF NUTRACEUTICALS IN AMELIORATING NEURODEGENERATION;275 12.6.9;CONCLUSION;276 12.6.10;References;276 12.7;Chapter 28 - The Role of Caffeine in Neurodegenerative Diseases: Possible Genetic and Cellular Signaling Mechanisms;284 12.7.1;Possible Genetic and Cellular Signaling Mechanisms;284 12.7.2;INTRODUCTION;284 12.7.3;THE GENETIC ROLE OF CAFFEINE IN ND;285 12.7.4;THE NON-GENETIC ROLE OF CAFFEINE IN NEURODEGENERATIVE DISEASES;289 12.7.5;CONCLUSION;295 12.7.6;References;295 12.8;Chapter 29 - Dietary Supplements as Cognitive Enhancers: The Role of Flavonoid-Rich Foods and their Relevance in Age-Related Neurodegeneration;304 12.8.1;The Role of Flavonoid-Rich Foods and their Relevance in Age-Related Neurodegeneration;304 12.8.2;INTRODUCTION;304 12.8.3;NEUROMODULATORY PATHWAYS UNDERLYING THE EFFECT OF FLAVONOIDS ON COGNITION;306 12.8.4;EFFECT OF FLAVONOIDS ON HORMETIC RESPONSE AND GUT MICROBIOTA;308 12.8.5;THE EFFECT OF FLAVONOIDS ON HUMAN COGNITIVE PERFORMANCE;309 12.8.6;CONCLUSION;309 12.8.7;References;311 13;SECTION V - MECHANISMS OF ACTION OF NUTRACEUTICALS AND DIETARY SUPPLEMENTS IN NEUROLOGICAL DISEASE THERAPY: AUTOIMMUNITY AND ANTIOXIDANT ACTIONS;314 13.1;Chapter 30 - Meat, Fat, and Fruit Consumption and Autoimmune Neurological and Brain Di
sease;316 13.1.1;OVERVIEW;316 13.1.2;INTRODUCTION;316 13.1.3;NUTRITION AND AUTOIMMUNE REGULATION;319 13.1.4;MULTIPLE SCLEROSIS;319 13.1.5;MYASTHENIA GRAVIS;322 13.1.6;ALZHEIMERS DISEASE;322 13.1.7;CONCLUSION;324 13.1.8;References;325 13.2;Chapter 31 - Ginsenosides as Food Supplements and Their Potential Role in Immunological and Neurodegenerative Disorders;326 13.2.1;INTRODUCTION;326 13.2.2;GINSENG CHEMISTRY;327 13.2.3;DIETARY SUPPLEMENTATION OF GINSENG;328 13.2.4;ROLE OF GINSENOSIDE IN THE IMMUNE SYSTEM AND IMMUNOLOGICAL DISORDERS;328 13.2.5;GINSENG AND INFLAMMATION-RELATED DISEASES;329 13.2.6;GINSENOSIDES AND THEIR APPLICATION IN NEUROLOGICAL AND NEURODEGENERATIVE DISORDERS;329 13.2.7;CONCLUSION;331 13.2.8;Acknowledgment;331 13.2.9;References;331 13.3;Chapter 32 - Antioxidant Actions of Spices and Their Phytochemicals on Age-Related Diseases;334 13.3.1;INTRODUCTION;334 13.3.2;SPICES IN HISTORY;335 13.3.3;CHEMICAL COMPOSITION OF SPICES;335 13.3.4;BIOLOGIC EFFECTS OF SPICES;336 13.3.5;SPICES AND ANTIOXIDANT ACTIVITY;337 13.3.6;MECHANISMS OF ACTION;338 13.3.7;EXPOSURE TO SPICES;339 13.3.8;CONCLUSION;339 13.3.9;References;340 13.4;Chapter 33 - Analgesic and Anti-Inflammatory Effects of Crocus sativus L. (Saffron);342 13.4.1;INTRODUCTION;342 13.4.2;CHEMICAL COMPOSITION;342 13.4.3;SAFFRON USES IN TRADITIONAL MEDICINE;343 13.4.4;PHARMACOLOGICAL STUDIES ON THE BIOLOGICAL ACTIVITY OF SAFFRON;343 13.4.5;ANTINOCICEPTIVE AND ANTI-INFLAMMATORY EFFECTS;343 13.4.6;References;345 13.5;Chapter 34 - Electrophilic Derivatives of Omega-3 Fatty Acids for the Cure and Prevention of Neurodegenerative Disorders;348 13.5.1;DIETARY MODULATION OF OMEGA-3 POLYUNSATURATED FATTY ACIDS IN CELL MEMBRANES AND ITS SIGNIFICANCE FOR NEURODEGENERATIVE DISORDERS...;348 13.5.2;ENDOGENOUS GENERATION OF ELECTROPHILIC PUFAS FROM OMEGA-3 FATTY ACIDS AND THEIR BIOLOGICAL SIGNIFICANCE;350 13.5.3;ELECTROPHILE-SENSITIVE PATHWAYS AND NEURODEGENERATIVE DISORDERS;353 13.5.4;ELECTROPHILIC PUFAS AS NOVEL DRUGS FOR
THE CURE AND PREVENTION OF NEURODEGENERATIVE DISORDERS;357 13.5.5;References;358 13.6;Chapter 35 - Antioxidants for the Prevention and Treatment of Multiple Sclerosis: An Overview;364 13.6.1;INTRODUCTION;364 13.6.2;ETIOLOGY AND PATHOGENESIS OF MS;365 13.6.3;OXIDATIVE STRESS, OXIDANTS, AND ANTIOXIDANTS;366 13.6.4;LIPOIC ACID;368 13.6.5;VITAMIN A;369 13.6.6;VITAMIN E;370 13.6.7;COENZYME Q10;371 13.6.8;CONCLUSION;372 13.6.9;References;372 13.7;Chapter 36 - High Caloric Diets in Amyotrophic Lateral Sclerois;378 13.7.1;INTRODUCTION;378 13.7.2;NUTRITION IN ALS;378 13.7.3;PERCUTANEOUS RADIOLOGICAL GASTROSTOMY AND PERCUTANEOUS ENDOSCOPIC GASTROSTOMY;379 13.7.4;HIGH-CALORIE DIETS IN ALS;379 13.7.5;NUTRACEUTICALS/DIETARY SUPPLEMENTS IN ALS;381 13.7.6;CALORIC RESTRICTION IN ALS;381 13.7.7;SUMMARY;381 13.7.8;References;382 14;SECTION VI - HYPERTENSION AND STROKE;386 14.1;Chapter 37 - Bioactive Nutraceuticals and Stroke:Activation of Endogenous Antioxidant Pathways and Molecular Mechanisms Underlying Neurovascular Protection;388 14.1.1;INTRODUCTION;388 14.1.2;NRF2: A REDOX SENSITIVE TRANSCRIPTION FACTOR AND REGULATOR OF CELLULAR ANTIOXIDANT DEFENSES;389 14.1.3;NUTRITION AND STROKE;390 14.1.4;NEUROVASCULAR PROTECTION IN STROKE BY PHYTONUTRIENTS;390 14.1.5;CLINICAL PERSPECTIVES AND CONCLUDING REMARKS;396 14.1.6;Acknowledgments;396 14.1.7;References;396 14.2;Chapter 38 - Oral Feeding in Patients with Intracerebral Hemorrhage: Risk versus Benefits;404 14.2.1;Risk versus Benefits;404 14.2.2;INTRODUCTION;404 14.2.3;MALNUTRITION AND DEHYDRATION;404 14.2.4;DYSPHAGIA;405 14.2.5;NONORAL FEEDING;405 14.2.6;DYSPHAGIA THERAPY;405 14.2.7;CONCLUSION;406 14.2.8;References;406 14.3;Chapter 39 - Neuroprotection by Dietary Isoflavones and Their Role in Cerebral Ischemia;408 14.3.1;INTRODUCTION;408 14.3.2;CEREBRAL ISCHEMIA;408 14.3.3;DIETARY ISOFLAVONES;409 14.3.4;CEREBRAL ISCHEMIA PREVENTION;410 14.3.5;CEREBRAL ISCHEMIA TREATMENT;411 14.3.6;REHABILITATION AND RECOVERY;411 14.3.7;MECHANISMS OF ACTI
ON;412 14.3.8;CONCLUSION;413 14.3.9;References;413 14.4;Chapter 40 - Vitamin K Antagonists (Coumarins), Drugs Used in the Prevention and Treatment of Cardioembolism, Deep Vein Thrombosis, and Pulmonary Embolism;418 14.4.1;VITAMIN K;418 14.4.2;References;421 14.5;Chapter 41 - Prevention of Ischemia-Induced Neuronal Apoptosis by Vitamin E in Stroke-Prone Spontaneously Hypertensive Rats: Cellular Mechanisms of Antioxidants;422 14.5.1;Cellular Mechanisms of Antioxidants;422 14.5.2;INTRODUCTION;422 14.5.3;EPIDEMIOLOGICAL STUDIES SUGGEST THAT VITAMIN E PROTECTS AGAINST STROKE;422 14.5.4;PREVENTION OF NEURONAL DEATH BY VITAMIN E IN SHRSP/IZM RATS;423 14.5.5;COMPARISON BETWEEN ANTIHYPERTENSION DRUGS AND VITAMIN E IN DECREASING SHRSP/IZM NEURONAL DEATH;424 14.5.6;CONCLUSION;425 14.5.7;References;425 14.6;Chapter 42 - Diet, Stroke, and Traumatic Brain Injury;426 14.6.1;INTRODUCTION;426 14.6.2;SOY;426 14.6.3;OMEGA-3 FATTY ACIDS;427 14.6.4;PHENOLICS;428 14.6.5;GINSENG;428 14.6.6;CONCLUSION;428 14.6.7;References;428 15;SECTION VII - SEIZURES, EPILEPSY,AND PARKINSONS DISEASE;432 15.1;Chapter 43 - A Plant-Food Diet in the Risk and Management of Parkinsons Disease;434 15.1.1;INTRODUCTION;434 15.1.2;EPIDEMIOLOGY OF PD;434 15.1.3;PHYSIOPATHOLOGY OF PD;435 15.1.4;ETIOLOGY OF PD;435 15.1.5;DIETARY RISK FACTORS IN PD;435 15.1.6;DIET AND LEVODOPA;436 15.1.7;LEVODOPA AND DIETARY PROTEIN;437 15.1.8;THE PROTEIN-REDISTRIBUTION DIET;437 15.1.9;A NEW STRATEGY: NORMOPROTEIC PROTEIN-REDISTRIBUTED PLANT-FOOD (VEGAN) DIET;438 15.1.10;PLANT-FOOD DIETS AND COMORBIDITY IN PD;438 15.1.11;NORMOPROTEIC PROTEIN-REDISTRIBUTED PLANT-FOOD (VEGAN) DIET: PRACTICAL ASPECTS;439 15.1.12;CONCLUSION;440 15.1.13;SUMMARY;441 15.1.14;References;441 15.2;Chapter 44 - Nutraceuticals and Other Natural Products in Parkinsons Disease Therapy: Focus on Clinical Applications;444 15.2.1;Focus on Clinical Applications;444 15.2.2;INTRODUCTION;444 15.2.3;VITAMINS AND PD;445 15.2.4;OMEGA FATTY ACIDS;446 15.2.5;COENZYME Q10;447 1
5.2.6;CITICOLINE;447 15.2.7;CREATINE;447 15.2.8;GLUTATHIONE;448 15.2.9;CARNOSINE;448 15.2.10;SPICES;448 15.2.11;TEA;448 15.2.12;CONCLUSIONS;448 15.2.13;References;449 15.3;Chapter 45 - Ketogenic Diet Treatment in Adults with Refractory Epilepsy;456 15.3.1;INTRODUCTION;456 15.3.2;KETOGENIC DIET;456 15.3.3;MODIFIED ATKINS DIET;459 15.3.4;CONCLUSION;461 15.3.5;References;461 15.4;Chapter 46 - Ketogenic Diets for the Treatment of Epilepsy;464 15.4.1;THE HISTORY OF THE KETOGENIC DIET;464 15.4.2;COMPOSITION, IMPLEMENTATION, AND MAINTENANCE OF THE CLASSIC KD;465 15.4.3;ALTERNATIVE FORMS OF DIETARY THERAPIES;465 15.4.4;SIDE EFFECTS;466 15.4.5;PROPOSED MECHANISM OF ACTION;467 15.4.6;INDICATIONS FOR KDS;467 15.4.7;THE KD AS A FIRST-LINE OR EARLY TREATMENT OF EPILEPSY;468 15.4.8;CONTRAINDICATIONS FOR THE USE OF THE KD;468 15.4.9;INTERACTIONS BETWEEN THE KD AND OTHER THERAPIES;468 15.4.10;THE KD AS A VIABLE LONG-TERM TREATMENT FOR EPILEPSY;469 15.4.11;THE FUTURE OF DIETARY THERAPIES;469 15.4.12;References;469 15.5;Chapter 47 - Nutritional/Metabolic Therapies in Animal Models of Amyotrophic Lateral Sclerosis, Alzheimers Disease, and Seizures;472 15.5.1;BACKGROUND;472 15.5.2;THERAPEUTIC KETOSIS AS A METABOLIC THERAPY;472 15.5.3;METABOLIC SUPPLEMENTATION;473 15.5.4;KD TREATMENT FOR SEIZURE DISORDERS;473 15.5.5;EFFICACY OF METABOLIC THERAPIES IN ANIMAL MODELS OF SEIZURE;474 15.5.6;NEURODEGENERATIVE DISEASES;475 15.5.7;METABOLIC THERAPIES IN MOUSE MODELS OF ALS;475 15.5.8;METABOLIC THERAPIES IN MOUSE MODELS OF AD;477 15.5.9;NEUROPROTECTIVE MECHANISM OF KETOSIS;478 15.5.10;CONCERNS;479 15.5.11;POTENTIAL FUTURE APPLICATION;480 15.5.12;References;480 15.6;Chapter 48 - Metabolic Dysfunctions in Epilepsy and Novel Metabolic Treatment Approaches;484 15.6.1;INTRODUCTION;484 15.6.2;GLYCOLYSIS PROVIDES ATP QUICKLY;485 15.6.3;IMPAIRMENTS OF GLYCOLYSIS IN EPILEPSY;486 15.6.4;IMPAIRMENTS OF THE TCA CYCLE IN EPILEPSY;486 15.6.5;ANTICONVULSANT EFFECTS OF CURRENT AND POTENTIAL METABOLIC TREATMENTS
;488 15.6.6;ANTICONVULSANT MECHANISMS AND THE METABOLIC EFFECTS OF METABOLIC THERAPIES;490 15.6.7;CONCLUSION;492 15.6.8;References;492 15.7;Chapter 49 - Vitamin D for the Prevention of Alzheimers Disease;498 15.7.1;INTRODUCTION;498 15.7.2;BASIC PHYSIOLOGY AND METABOLISM OF VITAMIN D;498 15.7.3;REFERENCE INTAKE FOR VITAMIN D;499 15.7.4;TREATING VITAMIN D DEFICIENCY;499 15.7.5;THEORIES LINKING VITAMIN D TO AD;500 15.7.6;CLINICAL TRIAL DATA;500 15.7.7;CONCLUSION;500 15.7.8;References;501 15.8;Chapter 50 - Is Multiple Sclerosis a Sun Deprivation Disease?: Lessons from the Past for the Future Path;504 15.8.1;Lessons from the Past for the Future Path;504 15.8.2;INTRODUCTION;504 15.8.3;MS;505 15.8.4;VITAMIN D: AN OVERVIEW;505 15.8.5;VITAMIN D AND IMMUNE FUNCTION;508 15.8.6;VITAMIN D AND MS;508 15.8.7;WHAT WE KNOW NOW: FINDINGS AND LIMITATIONS;511 15.8.8;CONCLUSION;512 15.8.9;References;514 16;Index;518